This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Boston Scientific MultiSENSE Study on HeartLogic Positive
by Zacks Equity Research
Boston Scientific (BSX) positive clinical trial data on HeartLogic should boost the Rhythm Management segment.
Becton, Dickinson Ultra-Fine Needle to Improve Diabetic Care
by Zacks Equity Research
Becton, Dickinson and Company's (BDX) latest micro pen needle will enhance the scope of its Diabetic Care unit.
Neogen (NEOG) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Neogen (NEOG) rides high on balanced growth across all business segments.
Halyard Health (HYH) Announces Positive Data on COOLIEF
by Zacks Equity Research
Halyard Health's (HYH) positive clinical data on COOLIEF will boost fortunes in the chronic pain space.
TransEntrix Progresses Toward FDA Approval for Senhance
by Zacks Equity Research
TransEnterix's (TRXC) gradual progress toward FDA's approval for Senhance Surgical Robotic System will boost its presence in the lucrative U.S. market.
Surmodics Receives FDA's Approval for PTA Balloon Catheter
by Zacks Equity Research
Surmodics (SRDX) receives FDA's approval for PTA Balloon Catheter, which will boost its presence in the global peripheral artery disease market.
Varian Medical (VAR) Releases FDA-Approved Eclipse 15.5
by Zacks Equity Research
Varian Medical (VAR) is consistently trying to turn around its Oncology Systems business.
Will Hurricanes Choke Cardiovascular (CSII) Q1 Performance?
by Zacks Equity Research
Cardiovascular (CSII) expects Q1 revenues to be affected by the Harvey and Irma hurricanes. However, the long-term growth prospects are unlikely to be affected.
Bruker (BRKR) Strong on Product Launches Amid Currency Woes
by Zacks Equity Research
Bruker (BRKR) continues to see solid contributions from NMR and Nano businesses. Also, a raised guidance is indicative of brighter prospects.
Masimo (MASI) Launches Rad-97 CO-Oximeter Post FDA Clearance
by Zacks Equity Research
Masimo's (MASI) newly-launched Rad-97 Pulse CO-Oximeter will strengthen the company's presence in the Advanced Monitoring Technologies space.
5 MedTech Stocks to Pick for Stellar Returns
by Zacks Equity Research
While the MedTech industry has been grappling with multiple issues, these stocks with high growth potential can be great bets.
McKesson to Gain From Distribution Business Amid Pricing Woes
by Zacks Equity Research
McKesson Corporation's (MCK) Distribution business driven by market growth and acquisitions is expected to aid growth. However, pricing remains a concern.
Varian Conducts Clinical Workshop, Strengthens Algeria Hold
by Zacks Equity Research
Varian (VAR) has 30 systems operating in Algeria at the moment. The latest development signifies the company's long-term goal of serving six million cancer patients every year.
AngioDynamics' BioFlo Platform Strong, Debt Levels High
by Zacks Equity Research
AngioDynamics' (ANGO) exclusive Endexo technology in the BioFlo unit is expected to enhance the company's growth trajectory. However, high debt levels limit the company's core business strategies.
Phibro Animal Health Expands Globally Amid Tough Competition
by Zacks Equity Research
Phibro (PAHC) is consistently trying to expand globally to counter the tough competition in the animal health and mineral nutrition space.
Allscripts' Latest Initiative Eradicates Price Ambiguity
by Zacks Equity Research
Lately, Allscripts' (MDRX) management has been focusing on various restructuring initiatives, research and development plans and launch of exclusive products.
Thermo Fisher Fundamentals Impressive Amid Tough Competition
by Zacks Equity Research
Thermo Fisher (TMO) continues to gain considerable synergies from FEI acquisition. A raised guidance buoys optimism.
Surmodics Presents Encouraging SurVeil DCB Data at VIVA Meet
by Zacks Equity Research
Surmodics' (SRDX) promising data on SurVeil DCB will boost its fortunes in the symptomatic peripheral artery disease space.
NuVasive Launches Breakthrough in MIS Surgery -- LessRay
by Zacks Equity Research
NuVasive's latest LessRay system reduces radiation emission and exposure. The stock is likely to gain on number of vital developments despite a brief dull phase in between.
Genomic Health Ties up With Biocartis, Boosts Oncotype DX
by Zacks Equity Research
Genomic Health's (GHDX) agreement with Biocartis will provide Genomic Health rights to develop and commercialize its Oncotype DX Breast Recurrence Score test on the Idylla platform.
Here's Why Investors Should Buy Luminex (LMNX) Right Now
by Zacks Equity Research
The market is upbeat about Luminex's (LMNX) recent partnership with Sutter Health and FDA approvals.
DaVita's (DVA) Green Initiatives Win a Coveted Golden Reward
by Zacks Equity Research
DaVita's (DVA) environment-friendly operations are likely to enhance the company's long-term sustainable growth. Also, strong patient services drive DaVita's success story.
Baxter (BAX) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Baxter (BAX) reaches a 52-week high on the back of an impressive product line. Buoyed by last quarter's stellar growth in earnings and sales, the company also raises long-term outlook.
Amedisys Rides High on Strong Prospects Amid Margin Woes
by Zacks Equity Research
Strength in Hospice and Personal Care businesses are offsetting the weakness in Amedisys' (AMED) Home Health Medicare business.
IDEXX Laboratories Rides High on Strong CAG, Global Growth
by Zacks Equity Research
IDEXX (IDXX) rides high on balanced segmental growth with significant contributions from the Companion Animal Group business. Moreover, strong fundamentals buoy optimism.